ACHV

Achieve Life Sciences Inc. Common Shares (ACHV)

Stock · NASDAQ · Health Care

$6.38as of 10/16/2026

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 25, 2026

ACHV: Downgrade noted, thesis intact; funding backs reset. Two recent SeekingAlpha articles discuss Achieve Life Sciences. One notes a rating downgrade but says the clinical thesis remains intact and the overall setup is still constructive. The other reports that the company has obtained funding to reset its manufacturing operations, indicating progress on the production side while keeping the clinical outlook unchanged.

Price chart

Open in TradingView

Active signals

BOLL Breakdown79.9%
High Beta65.1%
Support Confirmation43.4%200 SMA Touch0.0%
Support level
$6.07
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances

ACHV Signal Track Record

How signals performed across all stocks →

What ACHV's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike41-1.0%49%
Bollinger Band Breakout23-2.4%43%
Bollinger Band BreakdownActive now22+6.7%59%
200-Day Moving Average TouchActive now14-2.5%36%
Any 20-session window (baseline)-1.3%46%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About ACHV

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD an…

Sector
Health Care
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Employees
28

Fundamentals

1-day range
$6.22$7.02
Market cap
$672.42M
P/E (trailing)
—
P/E (forward)
-9.78
EPS (trailing)
$-1.55
Dividend yield
—
Beta
2.44
Avg. volume
1.40M
Dividend pay date
July 31, 2020
52-week range
$2.62$8.64
Next earnings: November 5, 2026 · EPS estimate $-0.19confirmed

Forecasts

13 analyst ratings

Buy 94%
Hold 6%
Sell 0%
1-year price forecast
High
$21
+229.4%
Median
$13
+103.9%
Low
$9
+41.2%

Achieve Life Sciences Inc. Common Shares Competitors

Chosen by industry and closest market cap.

  • ACHV
    Achieve Life Sciences Inc. Common Shares
    $6.38
    ▼ 8.46%
    Market cap $672.42MP/E —
    $2.62$8.64
  • TKNO
    Alpha Teknova Inc. Common Stock
    $7.08
    ▼ 6.84%
    Market cap $350.10MP/E —
    $1.91$9.48
  • MYGN
    Myriad Genetics Inc. Common Stock
    $3.98
    ▼ 8.51%
    Market cap $304.17MP/E —
    $2.74$8.59
  • QDEL
    QuidelOrtho Corporation Common Stock
    $12.91
    ▼ 7.19%
    Market cap $1.11BP/E —
    $9.92$35.58
  • IMDX
    Insight Molecular Diagnostics Inc. Common Stock
    $3.01
    ▼ 1.63%
    Market cap $154.99MP/E —
    $2.42$8.51
  • ICCC
    ImmuCell Corporation Common Stock
    $10.75
    ▲ 1.80%
    Market cap $99.70MP/E 121.11
    $4.52$12.1
  • QCLS
    Q/C Technologies Inc. Common Stock
    $0.538
    ▼ 3.58%
    Market cap $21.99MP/E —
    $0.4201$8.17

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Insider Activity

Insider Actions →
Acquired
466.9K
Disposed
20.6K
  • Halladay Benjamin · October 5, 2026 · Grant
    200.0K
  • Richard Alistair Stewart · August 19, 2026 · Sale
    20.6K @ $8.49
  • Reid Alexander Waldman · July 27, 2026 · Grant
    16.7K
  • Reid Alexander Waldman · July 27, 2026 · Grant
    25.0K
  • Martin Christopher Nathan · July 27, 2026 · Grant
    16.7K
  • Martin Christopher Nathan · July 27, 2026 · Grant
    25.0K
  • Sellig Thomas · July 27, 2026 · Grant
    16.7K
  • Sellig Thomas · July 27, 2026 · Grant
    25.0K
  • Phelan Nancy R. · July 27, 2026 · Grant
    16.7K
  • Phelan Nancy R. · July 27, 2026 · Grant
    25.0K
  • Royston Aaron · July 27, 2026 · Grant
    16.7K
  • Royston Aaron · July 27, 2026 · Grant
    25.0K
  • Richard Alistair Stewart · July 27, 2026 · Grant
    16.7K
  • Richard Alistair Stewart · July 27, 2026 · Grant
    25.0K
  • Jeffrey S. Farrow · July 27, 2026 · Grant
    16.7K

Institutional Ownership

March 31, 2026

Total shares held
21.81M
Total value held
$64.31M
Institutional holders
79
Top holders this quarter
  • Unknown4.37M
  • Unknown3.79M
  • Unknown2.20M
  • Unknown1.18M
  • Unknown1.08M
  • Unknown1.02M
  • Unknown728.4K
  • Unknown648.9K
  • Unknown641.9K
  • Unknown622.8K

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.